Shunji Haruta
Directeur Technique/Scientifique/R&D chez SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Postes actifs de Shunji Haruta
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Directeur Technique/Scientifique/R&D | 01/01/2011 | - |
| SATSUMA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 08/06/2023 | - |
Historique de carrière de Shunji Haruta
Statistiques
Internationale
| Japon | 2 |
| Etats-Unis | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sectorielle
| Commercial Services | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Commercial Services |
| Entreprise privées | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Bourse
- Insiders
- Shunji Haruta
- Expérience
